4.3 Article

Sphere-derived tumor cells exhibit impaired metastasis by a host-mediated quiescent phenotype

Journal

ONCOTARGET
Volume 6, Issue 29, Pages 27288-27303

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4803

Keywords

stem cell; dormancy; p27; osteolysis; p38

Funding

  1. Spanish Ministry of Economy and Competitiveness [BFU2011-22943, SAF2012-40056, FIS-PI13/00093]
  2. UTE project FIMA agreement, Cancer Research Thematic Network of Health Institute Carlos III [RTICC RD12/0036/0066]
  3. European Regional Development Fund (ERDF) Una manera de hacer Europa
  4. Marie Curie Grant [PIIF-GA-2010-275877]

Ask authors/readers for more resources

The spread of lung cancer cells to distant sites represents a common event associated with poor prognosis. A fraction of tumor cells named cancer stem cells (CSCs) have the ability to overcome therapeutic stress and remain quiescent. However, whether these CSCs have also the capacity to initiate and sustain metastasis remains unclear. Here, we used tumor sphere cultures (TSC) isolated from mouse and human lung cancer models to enrich for CSCs, and assessed their metastatic potential as compared to non-CSCs. As expected, TSC overexpressed a variety of stem cell markers and displayed chemoresistance. The CSC phenotype of TSC was confirmed by their higher growth ability in soft agar and tumorigenic potential in vivo, despite their reduced in vitro cell growth kinetics. Surprisingly, the appearance of spontaneous lung metastases was strongly delayed in mice injected with TSC as compared to non-TSC cells. Similarly, this finding was confirmed in several other models of metastasis, an effect associated with a retarded colonization activity. Interestingly, such delay correlated with a quiescent phenotype whose underlined mechanisms included an increase in p27 protein and lower phospho-ERK1/2 levels. Thus, these data suggest that cells enriched for CSC properties display an impaired metastatic activity, a finding with potential clinical implications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cell Biology

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

Karmele Valencia, Cristina Sainz, Cristina Bertolo, Gabriel de Biurrun, Jackeline Agorreta, Arantza Azpilikueta, Marta Larrayoz, Graziella Bosco, Carolina Zandueta, Miriam Redrado, Esther Redin, Francisco Exposito, Diego Serrano, Mirari Echepare, Daniel Ajona, Ignacio Melero, Ruben Pio, Roman Thomas, Alfonso Calvo, Luis M. Montuenga

Summary: There is a lack of adequate mouse models and cell lines for studying lung squamous cell carcinoma (LUSC). In this study, two models of transplantable LUSC cell lines were generated and characterized, revealing similar genetic and transcriptomic patterns. The immune landscape and response to immune checkpoint inhibition were also compared. Furthermore, the metastatic potential of these models showed organotropism similar to LUSC in humans. Overall, these valuable cell line tools recapitulate the complexity of the human disease.

DISEASE MODELS & MECHANISMS (2022)

Article Biochemistry & Molecular Biology

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Catia Monteiro, Lauritz Miarka, Maria Perea-Garcia, Neibla Priego, Pedro Garcia-Gomez, Laura Alvaro-Espinosa, Ana de Pablos-Aragoneses, Natalia Yebra, Diana Retana, Patricia Baena, Coral Fustero-Torre, Osvaldo Grana-Castro, Kevin Troule, Eduardo Caleiras, Patricia Tezanos, Pablo Muela, Elisa Cintado, Jose Luis Trejo, Juan Manuel Sepulveda, Pedro Gonzalez-Leon, Luis Jimenez-Roldan, Luis Miguel Moreno, Olga Esteban, Angel Perez-Nunez, Aurelio Hernandez-Lain, Jose Mazarico Gallego, Irene Ferrer, Rocio Suarez, Eva M. Garrido-Martin, Luis Paz-Ares, Celine Dalmasso, Elizabeth Cohen-Jonathan Moyal, Aurore Siegfried, Aisling Hegarty, Stephen Keelan, Damir Vareslija, Leonie S. Young, Malte Mohme, Yvonne Goy, Harriet Wikman, Jose Fernandez-Alen, Guillermo Blasco, Lucia Alcazar, Clara Cabanuz, Sergei Grivennikov, Andrada Ianus, Noam Shemesh, Claudia C. Faria, Rebecca Lee, Paul Lorigan, Emilie Le Rhun, Michael Weller, Riccardo Soffietti, Luca Bertero, Umberto Ricardi, Joaquim Bosch-Barrera, Elia Sais, Eduard Teixidor, Alejandro Hernandez-Martinez, Alfonso Calvo, Javier Aristu, Santiago M. Martin, Alvaro Gonzalez, Omer Adler, Neta Erez, Manuel Valiente

Summary: This study identifies a molecular mechanism underlying resistance to whole-brain radiotherapy and suggests potential targets and biomarkers for personalized radiotherapy. The findings have important implications for improving the efficacy of treatment for patients with brain metastasis.

NATURE MEDICINE (2022)

Review Oncology

YES1: A Novel Therapeutic Target and Biomarker in Cancer

Irati Garmendia, Esther Redin, Luis M. Montuenga, Alfonso Calvo

Summary: YES1, a nonreceptor tyrosine kinase, is considered as an emerging target in solid tumors. It is overexpressed in many tumor types, promoting cell proliferation and invasiveness. Novel specific inhibitors of YES1 have shown impressive antitumor effects in pre-clinical models. Inhibiting YES1 in tumors with high expression of this protein is a promising strategy against cancer.

MOLECULAR CANCER THERAPEUTICS (2022)

Review Biochemistry & Molecular Biology

Innate and Adaptive Responses of Intratumoral Immunotherapy with Endosomal Toll-Like Receptor Agonists

Fernando Torres Andon, Sergio Leon, Aldo Ummarino, Esther Redin, Paola Allavena, Diego Serrano, Clement Anfray, Alfonso Calvo

Summary: TLRs serve as natural initial triggers of immune responses and hold potential in cancer immunotherapy. Intratumoral injection of TLR agonists achieves high local drug exposure and strong antitumor response, potentially leading to cure and antitumor immunological memory.

BIOMEDICINES (2022)

Article Immunology

DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity

Karmele Valencia, Mirari Echepare, Alvaro Teijeira, Andrea Pasquier, Cristina Bertolo, Cristina Sainz, Ibon Tamayo, Benat Picabea, Graziella Bosco, Roman Thomas, Jackeline Agorreta, Jose Maria Lopez-Picazo, Joan Frigola, Ramon Amat, Alfonso Calvo, Enriqueta Felip, Ignacio Melero, Luis M. Montuenga

Summary: Valencia et al. have identified DSTYK as a novel therapeutic target in lung cancer. Inhibition of DSTYK sensitizes lung cancer cells to T cell-mediated killing and impairs mitochondrial fitness and cytoprotective autophagy. DSTYK copy number gain predicts lack of response to immunotherapy in lung cancer patients.

JOURNAL OF EXPERIMENTAL MEDICINE (2022)

Article Oncology

YES1 Is a Druggable Oncogenic Target in SCLC

Esther Redin, Eva M. Garrido-Martin, Karmele Valencia, Miriam Redrado, Jose Luis Solorzano, Rafael Carias, Mirari Echepare, Francisco Exposito, Diego Serrano, Irene Ferrer, Angel Nunez-Buiza, Irati Garmendia, Juana M. Garcia-Pedrero, Alfonso Gurpide, Luis Paz-Ares, Katerina Politi, Luis M. Montuenga, Alfonso Calvo

Summary: YES1 was identified as a novel targetable oncogene driving SCLC maintenance and metastasis, and its overexpression was associated with poor prognosis.

JOURNAL OF THORACIC ONCOLOGY (2022)

Article Oncology

Translation of a tissue epigenetic signature to circulating free DNA suggests BCAT1 as a potential noninvasive diagnostic biomarker for lung cancer

Cora Palanca-Ballester, David Hervas, Maria Villalba, Teresa Valdes-Sanchez, Diana Garcia, Maria Isabel Alcoriza-Balaguer, Marta Benet, Raquel Martinez-Tomas, Andres Briones-Gomez, Jose Galbis-Caravajal, Alfonso Calvo, Oscar Juan, Agustin Lahoz, Enrique Cases, Juan Sandoval

Summary: This study validates a noninvasive detection method using a 4-gene signature of DNA methylation levels for efficient diagnosis of lung cancer in plasma.

CLINICAL EPIGENETICS (2022)

Article Oncology

PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

Francisco Exposito, Miriam Redrado, Maeva Houry, Katherine Hastings, Magdalena Molero-Abraham, Teresa Lozano, Jose Luis Solorzano, Julian Sanz-Ortega, Vera Adradas, Ramon Amat, Esther Redin, Sergio Leon, Naroa Legarra, Javier Garcia, Diego Serrano, Karmele Valencia, Camila Robles-Oteiza, Giorgia Foggetti, Nerea Otegui, Enriqueta Felip, Juan J. Lasarte, Luis Paz-Ares, Jon Zugazagoitia, Katerina Politi, Luis Montuenga, Alfonso Calvo

Summary: Immunotherapy resistance in non-small cell lung cancer (NSCLC) can be attributed to an immunosuppressive microenvironment created by genetic alterations in the PTEN/PI3K/AKT/mTOR pathway and/or loss of PTEN expression. PTEN-low tumors are associated with higher levels of immune checkpoint proteins and poorer response to immunotherapy. Preclinical models demonstrate that PTEN loss promotes metastasis and fibrosis, and facilitates the conversion of immune cells into immunosuppressive regulatory T cells (Treg). However, targeting PTEN loss-mediated immunosuppression can reverse immunotherapy resistance in NSCLC.

CANCER RESEARCH (2023)

Review Oncology

Cancer Cell-Intrinsic Alterations Associated with an Immunosuppressive Tumor Microenvironment and Resistance to Immunotherapy in Lung Cancer

Nerea Otegui, Maeva Houry, Imanol Arozarena, Diego Serrano, Esther Redin, Francisco Exposito, Sergio Leon, Karmele Valencia, Luis Montuenga, Alfonso Calvo

Summary: Immunotherapy for NSCLC is effective for some patients, but less than half of them will benefit from it. Detection of PD-L1 in tumors is currently the only validated predictive biomarker. Genetic and metabolic alterations in tumor cells can affect the tumor microenvironment and the response to immunotherapy. Novel strategies based on these alterations may improve the efficacy of immunotherapy for lung cancer patients.

CANCERS (2023)

Editorial Material Oncology

Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Karmele Valencia, Luis M. Montuenga, Alfonso Calvo

Summary: The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) is inconclusive. However, a recent study suggests that the existence of a 17 beta-estradiol/ER alpha/PDL1 signaling loop in NSCLC is a key factor determining the response to immunotherapy, opening up new therapeutic options.

CLINICAL CANCER RESEARCH (2023)

Article Biochemistry & Molecular Biology

Presence of Activated (Phosphorylated) STAT3 in Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastases

Paola Anna Jablonska, Nuria Galan, Jennifer Barranco, Sergio Leon, Ramon Robledano, Jose Ignacio Echeveste, Alfonso Calvo, Javier Aristu, Diego Serrano

Summary: This study investigates the role of STAT3 and other inflammatory markers in the development of brain radiation necrosis (RN). The results suggest that STAT3 plays an important role in RN development, and targeting STAT3 may be a promising strategy for ameliorating symptomatic RN in brain metastases patients undergoing stereotactic radiosurgery (SRS).

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

No Data Available